What Albertsons Purchase of Rite Aid Means for Drug Retail
Albertsons is buying a big portion of Rite Aid to create a company worth $24 Billion. Shares of Rite Aid soared as much as 8 percent on the news. This acquisition comes as many retailers join forces to compete with Amazon, which is involved in nearly every industry from retail, to grocery, and now even healthcare. Wall Street Journal Reporter Heather Haddon and Bold Media's Business Editor David Grasso explain what this deal means for drug retail.
"Rite Aid was really put at a disadvantage right after the stuttered Walgreens deal," says Haddon. "This was really about Rite Aid helping to reposition themselves, get access to a whole new market of Albertsons customers, and in turn Albertsons gets a lot of pharmacy customers and cross-marketing opportunities."
"We are seeing a lot of disruption, and everyone is shaking in their boots," says Grasso. "It's all about survival.
Through this deal the integrated company will operate 4,900 locations, 4,350 pharmacy counters, and 320 clinics across 38 states and Washington, D.C.
It might not be what investors want to hear… but bringing down inflation could mean interest rates stay higher for (even) longer. But it's not all downside.
President Joe Biden and Chinese President Xi Jinping have discussed Taiwan, artificial intelligence and security issues in a call meant to demonstrate a return to regular leader-to-leader dialogue between the two powers.
April is Earth month, and while the green revolution might feel far away, the founder of climate VC Siam Capital says it’s on it’s way, and, even better: it won't cost you more.
From snow in April to heatwaves in December, it’s hard to plan a trip in a climate change world. Startup Sensible Weather thinks weather-based travel reimbursements are the solution.
Between corporate debt and the widening gap between ‘the haves and the have nots,’ there are reasons to be cautious about the economy, even with interest rate cuts on their way.
If the A.I. hype hasn’t given you enough of a reason to be excited (and a little terrified), the CEO of Zapata AI says the next frontier is designing bridges or creating pharmaceutical drugs.
